Cytosorbents (CTSO) Return on Capital Employed Growth (3y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -1,962.00 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 214.00 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 31.00 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 355.00 |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -846.00 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 1,318.00 |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -247.00 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 362.00 |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn | 879.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 879.00 |
| Dec 31, 2025 | 1,760.00 |
| Sep 30, 2025 | 2,390.00 |
| Jun 30, 2025 | 689.00 |
| Mar 31, 2025 | -127.00 |
| Dec 31, 2024 | -1,463.00 |
| Sep 30, 2024 | -3,458.00 |
| Jun 30, 2024 | -4,645.00 |
| Mar 31, 2024 | -6,141.00 |
| Dec 31, 2023 | -7,422.00 |
| Sep 30, 2023 | -5,128.00 |
| Jun 30, 2023 | -1,215.00 |
| Mar 31, 2023 | 840.00 |
| Dec 31, 2022 | 4,542.00 |
| Sep 30, 2022 | 3,787.00 |
| Jun 30, 2022 | 2,438.00 |
| Mar 31, 2022 | 2,619.00 |
| Dec 31, 2021 | 2,814.00 |
| Sep 30, 2021 | 2,702.00 |
| Jun 30, 2021 | 3,199.00 |
| Mar 31, 2021 | 3,764.00 |
| Dec 31, 2020 | 5,235.00 |
| Sep 30, 2020 | 4,262.00 |
| Jun 30, 2020 | 6,420.00 |
| Mar 31, 2020 | 31,969.00 |
| Dec 31, 2019 | 8,675.00 |
| Sep 30, 2019 | 3,544.00 |
| Jun 30, 2019 | 5,631.00 |
| Mar 31, 2019 | 5,690.00 |
| Dec 31, 2017 | 8,747.00 |
| Sep 30, 2017 | -849.00 |
| Jun 30, 2017 | -6,976.00 |
| Mar 31, 2017 | -29,988.00 |
| Dec 31, 2016 | 29,060.00 |
| Sep 30, 2016 | 88,312.00 |
| Jun 30, 2016 | 52,559.00 |
| Mar 31, 2016 | 7,659.00 |
| Dec 31, 2014 | 29,169.00 |
| Sep 30, 2014 | 16,160.00 |